{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-001553","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.306562+00:00","generated_at":"2026-05-26T03:39:27.814633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Q4 2024 IMCIVREE revenue $41.8M; cash runway extended to 2027","bullets":["Q4 2024 IMCIVREE net revenue $41.8M (+26% sequential, +73% YoY); FY2024 total $130.1M.","Net loss Q4 2024 ($44.6M) or ($0.72)/share vs ($41.6M) in Q4 2023; FY loss ($264.6M).","Raised ~$75M gross proceeds from ATM (1.3M shares at ~$56.30); cash $320.6M at Dec 31, 2024.","FDA and UK MHRA expanded IMCIVREE label to children as young as 2 years old.","Phase 3 acquired hypothalamic obesity trial topline data expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-001553","json":"https://secwatch.observer/filing/0001558370-25-001553.json","markdown":"https://secwatch.observer/filing/0001558370-25-001553.md","text":"https://secwatch.observer/filing/0001558370-25-001553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/0001558370-25-001553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:39:27.814633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}